PROBIOTICS: THE UNDERVALUED CONQUERORS
Abstract
ABSTRACT
Probiotics or beneficial microorganisms†have recently acquired the status of blockbusters in the pharmaceutical industry. Despite being commercially
available, little is known about the magnitude to which they can contribute to various disease conditions such as inflammatory bowel disease, allergy,
immunity, etc. this review dwells into the various mechanisms of actions of probiotics and summarizes the numerous benefits of these daily used
products, including the recent advances. It also emphasizes on the possible unfavorable consequences, which can result due to their extensive use.
Keywords: Probiotics, Allergy, Immunity, Inflammatory bowel disease.
Downloads
References
REFERENCES
Zilber-Rosenberg I, Rosenberg E. Role of microorganisms in the evolution of animals and plants: The hologenome theory of evolution. FEMS Microbiol Rev 2008;32(5):723-35.
Gorbach SL. Microbiology of the Gastrointestinal Tract. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.
O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7(7):688-93.
Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau P. Health benefits and health claims of probiotics: Bridging science and marketing. Br J Nutr 2011;106(9):1291-6.
Figueroa-González I, Quijano G, RamÃrez G, Cruz-Guerrero A. Probiotics and prebiotics – Perspectives and challenges. J Sci Food Agric 2011;91(8):1341-8.
Salazar N, Arboleya S, Valdés L, Stanton C, Ross P, Ruiz L, et al. The human intestinal microbiome at extreme ages of life. Dietary intervention as a way to counteract alterations. Front Genet 2014;5:406.
Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998;42(1):2-7.
Gupta V, Garg R. Probiotics. Indian J Med Microbiol 2009;27(3):202-9.
Gordon S. Elie Metchnikoff: Father of natural immunity. Eur J Immunol 2008;38(12):3257-64.
FAO/WHO. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food; 2002.
Bermudez-Brito M, Plaza-DÃaz J, Muñoz-Quezada S, Gómez-Llorente C,
Gil A. Probiotic mechanisms of action. Ann Nutr Metab 2012;61(12):160-74.
Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008;10(1-2):37-54.
Vandenplas Y, Huys G, Daube G. Probiotics: An update. J Pediatr (Rio J) 2015;91(1):6-21.
Fabian E, Majchrzak D, Dieminger B, Meyer E, Elmadfa I. Influence of probiotic and conventional yoghurt on the status of vitamins B1, B2 and B6 in young healthy women. Ann Nutr Metab 2008;52(1):29-36.
Fabian E, Elmadfa I. The effect of daily consumption of probiotic and conventional yoghurt on oxidant and anti-oxidant parameters in plasma of young healthy women. Int J Vitam Nutr Res 2007;77(2):79-88.
Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol 2008;42 Suppl 3:S111-5.
Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007;23(6):679-92.
Table 2: Functions of probiotics
Nutritional
Microbiological [13]
Physiological
Immunological
Increase level of Vitamin B1 and B2[14]
Antioxidant[15]
Production of conjugated linoleic acid
Improvement in lipid profile
Competing for the same niche
Competition for the nutrients
Production of toxins
Production of reactive superoxide radicals
Alteration of pH
Enhance GI Transit
Maintain the integrity if the gut barrier
Decrease the exposure of antigens to the immune cells
Fig. 1: Mechanism of action in infectious diarrhoea
Asian J Pharm Clin Res, Vol 8, Issue 4, 2015, 97-100
Kawatra and Aiyappa
Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci 2008;53(9):2524-31.
Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 2008;14(11):1585-96.
Yan F, Polk DB. Probiotics: Progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol 2010;26(2):95-101.
Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol 2011;26 Suppl 3:119-21.
Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006;55(2):182-90.
Camilleri M. Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006;40(3):264-9.
Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newbornsathogenesis, prevention and management. Drugs 2008;68(9):1227-38.
Panigrahi P. Necrotizing enterocolitis: A practical guide to its prevention and management. Paediatr Drugs 2006;8(3):151-65.
AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health 2014;9(3):584-671.
Demirel G, Erdeve O, Celik IH, Dilmen U. Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: A randomized, controlled study. Acta Paediatr 2013;102(12):e560-5.
Luedtke SA, Yang JT, Wild HE. Probiotics and necrotizing enterocolitis: Finding the missing pieces of the probiotic puzzle. J Pediatr Pharmacol Ther 2012;17(4):308-28.
Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr 1999;69(5):1046S-51S.
Gill HS, Shu Q, Lin H, Rutherfurd KJ, Cross ML. Protection against translocating S. typhimurium infection in mice by feeding the immuno-enhancing probiotic L. rhamnosus strain HN001. Med Microbiol Immunol 2001;190:97-104.
Haskard CA, El-Nezami HS, Kankaanpää PE, Salminen S, Ahokas JT. Surface binding of aflatoxin B(1) by lactic acid bacteria. Appl Environ Microbiol 2001;67(7):3086-91.
Coakley M, Ross RP, Nordgren M, Fitzgerald G, Devery R, Stanton C. Conjugated linoleic acid biosynthesis by human-derived Bifidobacterium species. J Appl Microbiol 2003;94(1):138-45.
Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S,
et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002;97(8):2150-2.
Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: A meta-analysis. Pediatrics 2002;109(4):678-84.
Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010:CD003048.
Isolauri E. Probiotics for infectious diarrhoea. Gut 2003;52(3):436-7.
Pereira DI, Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol 2002;37(4):259-81.
Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with Type 2 diabetes: A clinical trial. Iran J Med Sci 2013;38(1):38-43.
Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by L. acidophilus. Appl Environ Microbiol 1985;49(2):377-81.
Furrie E. Probiotics and allergy. Proc Nutr Soc 2005;64(4):465-9.
Yang G, Liu ZQ, Yang PC. Treatment of allergic rhinitis with probioticsn alternative approach. N Am J Med Sci 2013;5(8):465-8.
Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res 2007;62(2):215-20.
Fond G, Boukouaci W, Chevalier G, Regnault A, Eberl G, Hamdani N,
et al. The psychomicrobioticâ€: Targeting microbiota in major psychiatric disorders: A systematic review. Pathol Biol (Paris) 2015;63(1):35-42.
Galland L. The gut microbiome and the brain. J Med Food 2014;17(12):1261-72.
Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntyre RS. Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord Drug Targets 2014;13(10):1770-86.
Vitetta L, Bambling M, Alford H. The gastrointestinal tract microbiome, probiotics, and mood. Inflammopharmacology 2014;22(6):333-9.
Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46 Suppl 2:S104-11
Egervärn M, Roos S, Lindmark H. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J Appl Microbiol 2009;107(5):1658-68.
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121(4):e850-6.
Sharma P, Tomar SK, Goswami P, Sangwan V, Singh R. Antibiotic resistance among commercially available probiotics. Food Res Int 2014;57:176-95.
Wang HF, Lin PP, Chen CH, Yeh YL, Huang CC, Huang CY, et al. Effects of lactic acid bacteria on cardiac apoptosis are mediated by activation of the phosphatidylinositol-3 kinase/AKT survival-signalling pathway in rats fed a high-fat diet. Int J Mol Med 2015;35(2):460-70.
Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol 2014;20(43):16079-94.
de Moreno de LeBlanc A, LeBlanc JG. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol 2014;20(44):16518-28.
Fallucca F, Porrata C, Fallucca S, Pianesi M. Influence of diet on gut microbiota, inflammation and Type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev 2014;30 Suppl 1:48-54.
Porrata-Maury C, Hernández-Triana M, Ruiz-Ãlvarez V, DÃaz-Sánchez ME, Fallucca F, Bin W, et al. Ma-Pi 2 macrobiotic diet and Type 2 diabetes mellitus: Pooled analysis of short-term intervention studies. Diabetes Metab Res Rev 2014;30 Suppl 1:55-66.
Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014 14;20:15518-31.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.